Waleed H. Hassanein Sells 56,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) CEO Waleed H. Hassanein sold 56,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $8,566,679.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TransMedics Group Stock Up 2.9 %

TMDX stock opened at $127.99 on Friday. The stock has a market cap of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock’s fifty day simple moving average is $85.54 and its two-hundred day simple moving average is $77.08. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $129.66.

TransMedics Group (NASDAQ:TMDXGet Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same period in the previous year, the firm earned ($0.08) EPS. The firm’s quarterly revenue was up 132.9% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post 0.54 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently modified their holdings of the stock. Venturi Wealth Management LLC purchased a new position in TransMedics Group in the first quarter valued at approximately $30,000. Fidelis Capital Partners LLC bought a new stake in shares of TransMedics Group in the first quarter valued at $35,000. Cutler Group LLC CA lifted its position in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 600 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after acquiring an additional 222 shares during the period. Finally, RiverPark Advisors LLC purchased a new stake in TransMedics Group in the 3rd quarter worth about $60,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on TMDX. TD Cowen upped their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. Morgan Stanley lifted their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Oppenheimer upped their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $119.00.

Get Our Latest Research Report on TransMedics Group

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.